Sign in

    United Therapeutics Corp (UTHR)

    You might also like

    Business Description

    United Therapeutics Corporation (UTHR) is a biotechnology company dedicated to developing and commercializing innovative products for chronic and life-threatening conditions. The company focuses on addressing unmet medical needs through pharmaceutical therapies and technologies, particularly in the areas of pulmonary arterial hypertension (PAH) and oncology. UTHR also explores organ manufacturing technologies to expand the availability of transplantable organs.

    1. Tyvaso DPI - Provides inhalation powder therapy for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease .
    2. Nebulized Tyvaso - Offers inhalation solution for treating pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease .
    3. Remodulin - Delivers treprostinil injection for pulmonary arterial hypertension management .
    4. Orenitram - Supplies extended-release tablets for pulmonary arterial hypertension treatment .
    5. Unituxin - Provides dinutuximab injection for high-risk neuroblastoma in pediatric patients .
    6. Adcirca - Offers tadalafil tablets for pulmonary arterial hypertension .
    7. Other - Includes various other products contributing to the company's therapeutic offerings .

    Key Metrics

    View all financials →

    Executive Team

    NamePositionStart DateShort Bio
    Martine RothblattChairperson and Chief Executive Officer1996Martine Rothblatt, Ph.D., J.D., M.B.A. is the Founder, Chairperson, and CEO of United Therapeutics Corporation. She founded the company in 1996 and has served in her current roles since its inception .
    Michael BenkowitzPresident and Chief Operating Officer2016Michael Benkowitz joined United Therapeutics in 2011 as Executive Vice President, Organizational Development, and was promoted to President and COO in 2016 .
    James C. EdgemondChief Financial Officer and TreasurerMarch 2015James C. Edgemond joined United Therapeutics in January 2013 as Treasurer and Vice President, Strategic Financial Planning, and was promoted to CFO and Treasurer in March 2015 .
    Paul A. MahonExecutive Vice President, General Counsel, and Corporate Secretary2003Paul A. Mahon, J.D. has served as EVP, General Counsel, and Corporate Secretary since 2003. He joined United Therapeutics in 1996 as General Counsel and Corporate Secretary .
    Jan MalcolmBoard MemberJune 26, 2024Jan Malcolm was elected to the Board of Directors on June 26, 2024. She is a former Minnesota Commissioner of Health with a distinguished career in health policy and public health .
    Christopher CauseyChairman of the Nominating and Governance Committee2003Christopher Causey has been a director since 2003. He was the Principal of the Causey Consortium, providing business strategy and marketing counsel to the healthcare industry until his retirement in 2021 .
    Christopher PatuskyLead Independent Director and Vice Chair of the Board of Directors2002Christopher Patusky has served as a Director since 2002. He is the founding principal of Patusky Associates, LLC, and serves as an executive manager of Slater Run Vineyards, LLC .

    Questions to Ask Management

    1. Given the critical importance of the TETON trials for Tyvaso in pulmonary fibrosis, can you explain whether both ongoing studies need to succeed for FDA approval, or if one positive study could be sufficient?
    2. With the entrance of competitors like Merck into the PAH market, have you observed any changes in patient referrals or market dynamics that might affect your growth projections?
    3. Regarding capital allocation, how do you assess the potential for additional share buybacks or accelerated share repurchases in light of your investments in the xenotransplantation program?
    4. Can you elaborate on the drivers behind Tyvaso DPI's performance compared to Nebulized Tyvaso this quarter, and what factors are influencing patient and physician preference?
    5. While you've expressed confidence in the sustainability of your foundational products like Remodulin, Tyvaso, and Orenitram, what potential risks do you see that could impact their vitality, and how are you addressing them?